The SYK inhibitor market is poised for rapid growth, driven by increased interest in addressing unmet needs in autoimmune diseases, hematological conditions, and cancer. With ongoing clinical trials ...
The "SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Global SYK Inhibitor Market ...
Hutchmed has continued to test sovleplenib in wAIHA in parallel, culminating in the delivery of data from a Chinese phase 3 ...
Hutchmed is preparing to file for approval of a drug for the rare autoimmune disorder warm antibody autoimmune haemolytic ...
Chinese biopharma Hutchmed today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib ...
Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HONG KONG and SHANGHAI and ...
InvestorsHub on MSN
HUTCHMED shares edge higher after Phase III success for sovleplenib in wAIHA
Shares of HUTCHMED (NASDAQ:HCM) rose around 1.9% in premarket trading on Wednesday after the company reported positive Phase ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback